News
- Author:
- Jake Remaly
Publish date: May 30, 2019
SEATTLE – First-dose cardiac events with fingolimod are rare, regardless of whether first-dose observations occur in clinic or at home.
News
- Author:
- Jake Remaly
Publish date: May 30, 2019
SEATTLE – Distinguishing a multiple sclerosis relapse from a pseudorelapse is essential, according to a consensus statement.
News
- Author:
- Jake Remaly
Publish date: May 28, 2019
SEATTLE – Concomitant medication use is common when patients with multiple sclerosis start disease-modifying drugs (DMDs).
News
- Author:
- Jake Remaly
Publish date: May 28, 2019
SEATTLE – During 1999-2004, about 20% of patients with multiple sclerosis started treatment within 1 year of disease onset, compared with 60% of pa...
News
- Author:
- Jake Remaly
Publish date: May 28, 2019
SEATTLE – In a novel study, about half of patients with multiple sclerosis reported clinically significant symptoms of depression or pain, and appr...
News
- Author:
- Jake Remaly
Publish date: May 28, 2019
SEATTLE – Cytomegalovirus seropositivity may be associated with increased likelihood of multiple sclerosis in the Middle East and decreased likelih...
News
- Author:
- Jake Remaly
Publish date: May 21, 2019
The Food and Drug Administration has approved midazolam (Nayzilam) nasal spray for the acute treatment of intermittent, stereotypic episodes of fre...
News
- Author:
- Jake Remaly
Publish date: May 20, 2019
For stroke patients with a suspected large vessel occlusion, emergency medical services should consider up to 15 minutes of additional travel time ...
News
- Author:
- Jake Remaly
Publish date: May 11, 2019
PHILADELPHIA – Among patients with multiple sclerosis, consumption of sugar-sweetened beverages may be associated with more severe disability, acco...
News
- Author:
- Jake Remaly
Publish date: May 10, 2019
PHILADELPHIA – Nearly a quarter of adults with epilepsy have moderate or severe insomnia, and insomnia symptoms are associated with depression, anx...
News
- Author:
- Jake Remaly
Publish date: May 9, 2019
PHILADELPHIA – Efficacy in a phase 2 trial was driven by patients with primary progressive MS, which may be related to faster brain atrophy rates i...
News
- Author:
- Jake Remaly
Publish date: May 9, 2019
PHILADELPHIA – An orally dissolving tablet formulation has significant effects on pain relief and functional ability at 60 minutes post dose.
News
- Author:
- Jake Remaly
Publish date: May 9, 2019
PHILADELPHIA – In patients with amyotrophic lateral sclerosis caused by mutations in the SOD1 gene, an investigational treatment reduced SOD1 prote...
News
- Author:
- Jake Remaly
Publish date: May 7, 2019
The mean duration of treatment was about 90 days longer among those treated with spironolactone than among those on oral tetracyclines.
News
- Author:
- Jake Remaly
Publish date: May 7, 2019
DALLAS – Clinical and imaging findings may indicate disease phase, severity, and prognosis, which can inform the treatment choice.
